Tours CHU
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VILLATE, Alban
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Recruiting
N/A
230
Europe
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult
12/24
03/25
ALHERT, NCT06409767: Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

Not yet recruiting
N/A
2224
Europe
Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
University Hospital, Angers
Leukemia, Lymphoma, Multiple Myeloma
10/27
01/28

Download Options